🔍

INDOCO - Indoco Remedies

📊 NSE: INDOCO 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 8:02

📢 Recent Corporate Announcements

Indoco Remedies to Participate in 11th Annual Valorem Conference on March 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 03:25 PM

Indoco Remedies Limited has scheduled a meeting with analysts and institutional investors on March 23, 2026. The senior management will participate in the 11th Annual Valorem Conference titled "Resilient Corporates, Relentless India" in Mumbai. The interaction is planned as a physical group meeting starting at 09:00 am at the Grand Hyatt, Santacruz. The company has explicitly stated that no unpublished price sensitive information will be shared during this interaction.

Participation in the 11th Annual Valorem Conference scheduled for March 23, 2026
Senior management to engage in group meetings with institutional investors and analysts
Physical interaction to take place at Grand Hyatt, Santacruz (East), Mumbai
Meeting organized by Valorem Advisors starting at 09:00 am
Company confirms no unpublished price sensitive information (UPSI) will be disclosed

💡 Investors should monitor for any post-conference investor presentations or transcripts that may provide qualitative insights into the company's growth outlook. No immediate trading action is required based on this routine disclosure.

Indoco Remedies Receives Final USFDA Approval for Brivaracetam Oral Solution

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 24 Feb 2026, 11:50 AM

Indoco Remedies has secured final ANDA approval from the USFDA for Brivaracetam Oral Solution (10 mg/mL), a generic version of UCB's Briviact. This antiepileptic drug is used for treating partial-onset seizures in patients as young as 1 month old. The product will be manufactured at the company's USFDA-approved facility in Goa, India. This approval marks a significant milestone in Indoco's strategy to expand its presence in the high-value regulated US market.

Final USFDA approval received for Brivaracetam Oral Solution, 10 mg/mL
Generic equivalent to the reference listed drug Briviact by UCB, Inc.
Manufacturing to be conducted at the company's Goa facility (L-14, Verna Industrial Area)
Indoco maintains a global turnover of US$ 180 million with 10 manufacturing facilities
Target therapeutic area is antiepileptic treatment for patients 1 month and older

💡 Investors should monitor the commercial launch timeline and potential market share capture in the US generic market. This approval strengthens the company's export portfolio and could contribute to margin expansion in the upcoming quarters.

Indoco Remedies Q3 FY26: Cons. Revenue Up 7.9% YoY to ₹434 Cr; EBITDA Margins Expand to 7.3%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 09 Feb 2026, 05:58 PM

Indoco Remedies reported a 7.9% YoY increase in consolidated revenue to ₹4,343 million for Q3 FY26, supported by a 26.2% growth in international formulations. Consolidated EBITDA margins improved to 7.3% from 3% YoY, even after accounting for ₹8-9 crore in non-recurring remediation costs and penalties. While the domestic business remained flat due to pressure in acute therapies, the company improved its prescription ranking to 21st in IQVIA audits, surpassing Pfizer. The Patalganga API site successfully received a USFDA EIR with zero 483 observations, strengthening its regulatory profile.

Consolidated revenue grew 7.9% YoY to ₹4,343 million, while API business surged 24% to ₹344 million.
International formulations saw robust growth of 26.2% YoY, with Europe growing 36.9% and the US up 21.6%.
EBITDA margins expanded to 7.3% from 3% YoY, despite one-time remediation and penalty costs of approximately ₹8-9 crore.
The company reached the 21st rank in IQVIA prescription audits with a total of 10.86 crore prescriptions.
Patalganga API facility received USFDA EIR with zero 483 observations; Goa Plant II status remains under watch.

💡 Investors should monitor the recovery in the domestic acute segment and the resolution of USFDA issues at the Goa Plant II. The expansion in API and international margins is a positive sign for long-term profitability and operational efficiency.

Indoco Remedies Announces Conclusion of GST Search by Maharashtra Authorities

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 09 Feb 2026, 05:37 PM

Indoco Remedies Limited has reported the conclusion of a GST inspection and search by the Maharashtra State GST Department. The search, which was initiated around February 3, 2026, officially concluded on February 8, 2026, at 8:15 PM. The company has provided all requested documents and clarifications to the authorities during the process. Currently, no official order or demand notice has been issued, and the company maintains that there is no material impact on its financial or operational activities.

Maharashtra State GST Department concluded its search on February 8, 2026, at 20:15 IST.
The inspection was conducted under Section 67 of the Maharashtra Goods & Service Tax Act, 2017.
No official document or violation notice has been issued to the company following the search.
Management confirms no material impact on the company’s financials or operations due to this event.

💡 Investors should view this as a routine regulatory update since no financial demand has been raised yet. Continue to monitor for any future show-cause notices that may arise from the findings of this inspection.

Indoco Remedies Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 03 Feb 2026, 06:40 PM

Indoco Remedies has officially released the audio recording of its earnings conference call for the quarter and nine months ended December 31, 2025. The call, conducted on February 3, 2026, provides management's perspective on the company's unaudited standalone and consolidated financial performance. This disclosure is part of the mandatory compliance under SEBI Listing Obligations and Disclosure Requirements. Investors can access the recording via the company's website to gain insights into operational trends and future guidance.

Earnings conference call conducted on February 3, 2026, following Q3 results.
Covers financial performance for the nine-month period ending December 31, 2025.
Recording made available on the company's official website under the investor section.
The call duration was approximately 58 minutes, concluding at 4:28 p.m. IST.
Compliance filing submitted under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should listen to the recording to understand management's commentary on margin pressures or growth drivers in the pharma sector. This is a routine update and does not contain new material financial data beyond what was in the earnings report.

Indoco Remedies Q3 Results: Consolidated Loss Widens to ₹29.45 Cr Amid Subsidiary Concerns

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 11:59 AM

Indoco Remedies reported a consolidated net loss of ₹29.45 crore for the quarter ended December 31, 2025, compared to a loss of ₹28.40 crore in the previous year. While consolidated revenue grew 8.5% YoY to ₹445.36 crore, the bottom line was hit by rising finance costs and an exceptional charge of ₹6.94 crore related to New Labour Code liabilities. A significant concern is the auditor's 'Emphasis of Matter' regarding two subsidiaries, FPP Holding LLC and Warren Remedies, which have substantial negative net worth and material uncertainty regarding their status as going concerns.

Consolidated revenue from operations rose 8.5% YoY to ₹445.36 crore in Q3FY26.
Reported a consolidated net loss of ₹29.45 crore for the quarter.
Exceptional loss of ₹6.94 crore recognized due to implementation of New Labour Codes affecting employee benefits.
Auditors flagged material uncertainty for subsidiaries FPP Holding LLC and Warren Remedies with a combined negative net worth exceeding ₹93 crore.
Finance costs increased significantly to ₹25.64 crore from ₹16.11 crore in the year-ago quarter.

💡 Investors should remain cautious due to persistent losses and the auditor's warning regarding the financial health of key subsidiaries. Monitor the company's ability to manage its rising finance costs and the turnaround strategy for its international operations.

Indoco Remedies Reports GST Search at Registered Office for FY 2020-21 Onwards

🔵 WATCH ⭐ 6/10

REGULATORY 📅 03 Feb 2026, 11:16 AM

GST authorities from the Maharashtra State GST Department conducted a search at Indoco Remedies' registered office on February 2, 2026. The inspection, carried out under Section 67 of the CGST and SGST Act, involves the verification of books of accounts for the period from 2020-2021 to the present. The company has stated that the proceedings are ongoing and they are cooperating fully with the authorities. As of now, no specific allegations have been made and no financial impact has been quantified.

Maharashtra State GST Department initiated search and seizure proceedings on February 2, 2026.
The investigation covers a five-year period of books of accounts from FY 2020-2021 to date.
Action taken under Section 67 of the CGST Act and SGST Act (Power to Inspect, Search and Seizure).
No specific violations or monetary demands have been communicated by the authorities so far.

💡 Investors should monitor future disclosures for any tax demands or penalties resulting from this search. While the search creates short-term uncertainty, the final impact will depend on the findings of the GST department.

Indoco Remedies Allots 55,700 Equity Shares Under ESOP 2022 Plan

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Feb 2026, 09:38 AM

Indoco Remedies has approved the allotment of 55,700 equity shares to the Indoco Employees Welfare Trust under its 2022 ESOP scheme. The allotment consists of 42,300 shares at an exercise price of Rs. 307 and 13,400 shares at a face value price of Rs. 2. This transaction has increased the company's total paid-up equity capital to Rs. 18.46 crore. The total amount raised through this exercise is approximately Rs. 1.30 crore.

Allotment of 55,700 equity shares of face value Rs. 2 each approved on February 3, 2026
Total paid-up capital increased from 9,22,47,905 to 9,23,03,605 equity shares
Exercise prices were bifurcated into 42,300 shares at Rs. 307 and 13,400 shares at Rs. 2
Total capital infusion from the exercise amounts to Rs. 1,30,12,900

💡 This is a routine administrative matter with negligible equity dilution. No specific action is required from investors based on this announcement.

Indoco Remedies Receives USFDA Final Approval for Lacosamide Oral Solution

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 30 Jan 2026, 01:23 PM

Indoco Remedies has received final ANDA approval from the USFDA for Lacosamide Oral Solution USP, 10 mg/mL, a generic version of UCB's Vimpat. The product is indicated for treating seizures in epilepsy patients aged 4 years and older. Manufacturing will take place at the company's Goa facility, supporting Indoco's global expansion strategy. With a current turnover of US$ 180 million, this approval adds a key product to Indoco's US portfolio.

Final ANDA approval granted for Lacosamide Oral Solution USP, 10 mg/mL
Generic equivalent to the Reference Listed Drug (RLD) Vimpat Oral Solution by UCB, Inc.
Product to be manufactured at the USFDA-approved facility in Verna, Goa
Indicated for partial onset and primary generalized tonic-clonic seizures
Indoco maintains a global turnover of US$ 180 million with 11 manufacturing facilities

💡 Investors should view this as a positive development that strengthens Indoco's US generic pipeline. Monitor the product's commercial launch and its contribution to the company's export revenue in the coming quarters.

Indoco Remedies to Host Q3FY26 Earnings Conference Call on February 3, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 20 Jan 2026, 11:44 AM

Indoco Remedies Limited has scheduled its earnings conference call to discuss the unaudited financial results for the third quarter and nine months ended December 31, 2025. The call is slated for Tuesday, February 3, 2026, at 3:30 PM IST and will be hosted by Nirmal Bang Institutional Equities. Key management personnel, including the Managing Director and CFO, will be present to address queries regarding the company's performance. This is a routine regulatory filing following the end of the reporting period.

Earnings call scheduled for February 3, 2026, at 3:30 PM IST
Focus on financial results for the quarter and nine months ended December 31, 2025
Management representation includes MD Aditi Panandikar and CFO Pramod Ghorpade
Call hosted in coordination with Nirmal Bang Institutional Equities

💡 Investors should mark the date to listen to management commentary on margin trends and growth outlook; no immediate action is required until results are published.

Indoco Remedies Submits SEBI Compliance Certificate for Quarter Ended December 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 06:17 PM

Indoco Remedies Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms that securities received for dematerialization during the quarter ended December 31, 2025, were processed within prescribed timelines. It verifies that security certificates were mutilated and cancelled after due verification and the depositories' names were updated in the register of members. No requests for rematerialization were reported during this period.

Compliance certificate issued for the quarter ended December 31, 2025.
Confirmation that all dematerialization requests were accepted or rejected within regulatory timelines.
Verification that security certificates were mutilated and cancelled after processing.
Zero rematerialization requests were received by the Registrar during the quarter.

💡 This is a routine regulatory filing with no impact on the company's fundamentals. No action is required from investors.

Indoco Remedies to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Dec 2025, 07:13 PM

Indoco Remedies Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This closure is a mandatory regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the release of financial results for the quarter and nine months ending December 31, 2025. The window will remain closed until 48 hours after the standalone and consolidated financial results are declared. This is a standard procedure to prevent insider trading during the period when sensitive financial data is being finalized.

Trading window closure effective from January 1, 2026.
Closure relates to the financial results for the quarter and nine months ended December 31, 2025.
Trading restriction ends 48 hours after the official declaration of results.
Applies to all designated persons and their immediate relatives as per SEBI norms.

💡 This is a routine regulatory filing with no impact on company fundamentals; investors should monitor the upcoming board meeting date for the actual Q3 FY26 earnings release.

Indoco Remedies Promoters Transfer 6% Direct Stake to Kare Family Trust for Succession Planning

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 30 Dec 2025, 05:32 PM

Kare Family Private Trust (KFPT) has acquired a 6.00% direct stake (55,34,874 shares) in Indoco Remedies from promoter Aruna Suresh Kare. In addition to the direct stake, the trust acquired indirect control through stakes in promoter entities Shanteri Investment Private Limited and SPA Holdings Private Limited. This transaction is an inter-se off-market transfer intended for smooth succession planning and streamlining family assets. Since the transfer is among immediate relatives, it is exempt from open offer requirements under SEBI (SAST) Regulations.

Direct acquisition of 55,34,874 equity shares representing 6.00% of the total share capital.
KFPT's direct shareholding in Indoco Remedies increased from 8.20% to 14.20% post-transaction.
Indirectly acquired 40% of Shanteri Investment and 20.16% of SPA Holdings, which hold 17.19% and 19.88% of the company respectively.
The transfer was executed at nil consideration as a private family arrangement.
The transaction is exempt from open offer obligations under Regulation 10(1)(a)(i) of SEBI (SAST) Regulations.

💡 This is an internal restructuring within the promoter group for succession planning and does not impact the company's fundamentals. Investors should remain focused on the company's quarterly earnings and operational performance.

Indoco Remedies to Participate in Dolat Capital Corporate Conference on Feb 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Dec 2025, 10:24 PM

Indoco Remedies Limited has scheduled a meeting with analysts and institutional investors for February 18, 2026. The company's senior management will participate in the Dolat Capital Corporate Conference 2026, themed 'Decoding Growth Strategies', in Mumbai. This interaction is a physical group meeting aimed at discussing the company's broad strategic direction. The company has explicitly stated that no unpublished price sensitive information will be disclosed during this event.

Meeting scheduled for February 18, 2026, at Grand Hyatt, Mumbai
Participation in Dolat Capital Corporate Conference 2026 focused on growth strategies
Senior management to engage in a physical group meeting with institutional investors
Disclosure made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015

💡 No immediate action is required as this is a routine investor engagement. Investors should monitor for any post-conference presentations or transcripts that may provide insights into the company's future growth outlook.

Indoco Remedies Promoters to Transfer 6% Stake to Family Trust for Succession Planning

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 18 Dec 2025, 12:37 PM

Promoter Aruna Suresh Kare is set to transfer 55,34,874 equity shares, representing a 6% stake in Indoco Remedies, to the Kare Family Private Trust (KFPT). This is an inter-se transfer among promoters intended for smooth succession planning and streamlining of family assets. The transaction also involves indirect transfers of stakes in promoter entities Shanteri Investment Private Limited and SPA Holdings Private Limited. As this is a private family arrangement, the transfer will occur at nil consideration and will not change the aggregate promoter group holding.

Direct transfer of 55,34,874 shares (6% stake) from Aruna Suresh Kare to Kare Family Private Trust.
Indirect acquisition of 40% stake in Shanteri Investment Pvt Ltd and 20.16% in SPA Holdings Pvt Ltd.
The transaction is an off-market inter-se transfer with zero cash consideration.
KFPT's direct shareholding in the company will increase from 8.20% to 14.20% post-acquisition.
The proposed date of acquisition is on or after December 25, 2025.

💡 Investors should view this as a routine internal restructuring for estate planning purposes that does not impact the company's fundamentals or overall promoter control. No action is required as the total promoter holding remains stable.

View All INDOCO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Domestic Formulations revenue was INR 2,261 Mn in Q2 FY26, a decline of 3.6% YoY. International Formulations grew 21.5% YoY to INR 1,533 Mn. API revenue surged 43% YoY to INR 431 Mn. Allied Services (CRO & IAS) grew 83.8% YoY to INR 68 Mn.

Geographic Revenue Split

Domestic business contributes 53% of standalone revenue. International markets contribute 36%, with the US at INR 336 Mn (up 36% YoY), Europe at INR 547 Mn (down 8.7% YoY), and Emerging Markets at INR 618 Mn (up 56% YoY).

Profitability Margins

Consolidated PAT margin was -2.0% in Q2 FY26 compared to -2.3% YoY. Standalone EBITDA margin stood at 12.4% in Q2 FY26, down from 13.4% YoY. H1 FY26 consolidated PAT margin was -5.0%.

EBITDA Margin

Consolidated EBITDA margin was 9.1% in Q2 FY26, a slight decrease from 9.3% in Q2 FY25. Standalone EBITDA margin for H1 FY26 was 8.4%, down from 13.2% YoY, primarily due to increased operating expenses and supply-side disruptions.

Capital Expenditure

The company is undergoing a Master Manufacturing Plan (MMP) involving significant refurbishment of manufacturing plants. While specific total INR Cr is not disclosed, these investments are intended to modernize facilities and address global pricing pressures.

Credit Rating & Borrowing

Long-term rating is [ICRA]A (Negative), downgraded from [ICRA]A+ (Negative). Short-term rating reaffirmed at [ICRA]A2+. Finance costs rose 38% YoY to INR 246 Mn in Q2 FY26 due to high debt levels (Net Debt to Equity of 0.68).

⚙️ Operational Drivers

Raw Materials

Key Starting Materials (KSMs) for API production and various packaging materials. Specific chemical names and their % of total cost are not disclosed in available documents.

Capacity Expansion

Current capacity includes 11 manufacturing facilities (7 FDF and 4 API). Planned expansion is focused on the Master Manufacturing Plan (MMP) refurbishment and the completion of finished product construction at the Warren Remedies API site.

Raw Material Costs

Profitability is vulnerable to fluctuations in raw material and packaging costs. Raw material costs are managed through the MMP to improve efficiency, though specific YoY % changes for raw materials are not disclosed.

Manufacturing Efficiency

Efficiency is currently impacted by plant refurbishments. The company aims to improve EBITDA returns in Europe and Emerging Markets through on-ground presence and branded business focus.

Logistics & Distribution

The company received the 'Next 5 (Top) Supply Chain & Logistics Award' from Alden Global Value Advisors, indicating recognized distribution capabilities.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth will be achieved by expanding Indoco UK (launched Nov 2024), scaling the OTC/OTX business (Warren Remedies) which grew 40% YoY, and 'owning the chain' by buying back assets from partners like Teva to control launch timelines and margins.

Products & Services

Medicines (Domestic and International Formulations), Active Pharmaceutical Ingredients (APIs), and Allied Services including Clinical Research (CRO) and Analytical Solutions.

Brand Portfolio

Cyclopam, Oxipod, Febrex Plus, ATM, Cital, Atherochek, Vepazil, Tuspel AA, Braceness, Multifibro, and Toco Fibro.

New Products/Services

Launched 6 new products in Q2 FY26: Vepazil 250/500, Tuspel AA, Braceness Toothpaste, Multifibro Capsule, and Toco Fibro Capsule.

Market Expansion

Indoco UK will begin sales operations in Nov 2025 with 3 products. The company also signed multiple B2B deals across Eastern Europe in FY25 to expand its core portfolio reach.

Market Share & Ranking

Ranked 31st in the Indian Pharmaceutical Market (IPM) with a 0.56% market share and 20th in prescription ranking as of September 2025.

Strategic Alliances

Previously partnered with Teva; currently buying back assets to own future product launches. Strategic B2B partnerships are being pursued in Europe and Emerging Markets.

🌍 External Factors

Industry Trends

The European generic market is valued at Euro 103 billion, presenting a key focus area. There is a shift toward branded generics in Emerging Markets where Indoco is focusing on on-ground personnel.

Competitive Landscape

Key competitors include global generic players and local manufacturers in international markets. Indoco competes through high brand equity and customer trust.

Competitive Moat

Durable advantages include a 70-year legacy in India, a strong R&D focus on complex ophthalmics, and a top-20 ranking in prescription generation, which are sustainable through continued pipeline investment.

Consumer Behavior

Shift toward sub-chronic care and increased demand for OTC oral care products in the Indian market.

Geopolitical Risks

Vulnerable to trade barriers and stiff competition from low-priced generics and locally manufactured products in Emerging Markets.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by USFDA manufacturing standards and domestic pricing controls under the National List of Essential Medicines (NLEM).

⚠️ Risk Analysis

Key Uncertainties

Regulatory constraints at sterile manufacturing plants and supply-side disruptions from the Master Manufacturing Plan (MMP) refurbishment, which impacted H1 FY26 performance.